The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273
Open accessAbstract
The United States Food and Drug Administration recently issued emergency use authorization for 2 mRNA vaccines for preventing COVID-19 disease caused by SARS-CoV-2 virus infections. BNT162b2 from Pfizer-BioNTech and mRNA-1273 by Moderna are planned for use in mass-immunization programs to curb the pandemic. A brief overview of COVID-19 mRNA vaccines is provided, describing the SARS-CoV-2 RNA, how mRNA vaccines work and the advantages of mRNA over other vaccine platforms. The Pfizer-BioNTech collaboration journey to short-list mRNA vaccine candidates and finally selecting BNT162b2 based on safety data is outlined, followed by the Phase 3 study of BNT162b2 demonstrating 95% efficacy in preventing COVID-19 infections. Studies regarding mRNA-1273 (Moderna) are described, including extended immunogenicity data up to 119 days. The Phase 3 COVE study of mRNA-1273 eventually showed vaccine efficacy of 94.5%. Recommendations for future mRNA vaccine development are provided, including ongoing safety surveillance, evaluation in under-represented groups in previous studies and improving mRNA vaccine thermostability. Finally, further logistical considerations are required for manufacturing, storing, distribution and implementing mass vaccination programs to curb the pandemic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with similar immune responses among adolescents aged 12 to 17.410,412–414”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [413]
In the citing paper
“In a phase III clinical trial involving 30,420 people, participants aged 18 or older were given two doses of 100 μg of mRNA-1273 with a 28-day interval, and vaccine efficacy was 94.1% (Table 5)”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [413]
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“Although the duration of protection from a singledose remains uncertain, a second dose does not appear to confer much additional benefit for the vaccine recipients.(29) In the Moderna trial, 81 (0.”
BackgroundCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 1×
“During the phase 1, dose-escalation trial, 45 healthy adults aged 18 to 55 years were administered 2 doses of 25 mg, 100 mg or 250 mg of mRNA-1273 28 days apart.(18) In this study, there was a dose-dependent antibody response; with increasing titers and serum-neutralizing activity after the second vaccination at the u…”
MethodRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2032195 · Cited by 722
A thermostable mRNA vaccine against COVID-19
Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 671
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
Developing mRNA-vaccine technologies
Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology · doi:10.4161/rna.22269 · Cited by 622
Addressing the Cold Reality of mRNA Vaccine Stability
Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W., & Mastrobattista, E. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.006 · Cited by 517
The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation
Wang, J., Peng, Y., Xu, H., Cui, Z., & Williams, R. O. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01744-7 · Cited by 335
Mechanism of action of mRNA-based vaccines
Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1355245 · Cited by 234
Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment
Koyama, T., Weeraratne, D., Snowdon, J. L., & Parida, L. (2020) · Pathogens · doi:10.3390/pathogens9050324 · Cited by 223
Li, M., Zhao, M., Fu, Y., Li, Y., Gong, T., Zhang, Z., & Sun, X. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.043 · Cited by 201
Brito, L. A., Kommareddy, S., Maione, D., Uematsu, Y., Giovani, C., Scorza, F. B., Otten, G. R., Yu, D. L., Mandl, C. W., Mason, P. W., et al. (2014) · Advances in genetics · doi:10.1016/bs.adgen.2014.10.005 · Cited by 181
Should We Mandate a COVID-19 Vaccine for Children?
Opel, D. J., Diekema, D. S., & Ross, L. F. (2021) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2020.3019 · Cited by 124
Helfand, B., Webb, M. A., Gartaganis, S. L., Fuller, L., Kwon, C., & Inouye, S. K. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.5084 · Cited by 97
Planning for COVID-19 vaccines safety surveillance
Kochhar, S., & Salmon, D. A. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.07.013 · Cited by 87
Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults
Cox, L. S., Bellantuono, I., Lord, J. M., Sapey, E., Mannick, J. B., Partridge, L., Gordon, A. L., Steves, C. J., & Witham, M. D. (2020) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(20)30011-8 · Cited by 73
Kinsella, C. M., Santos, P. D., Postigo-Hidalgo, I., Folgueiras-González, A., Passchier, T. C., Szillat, K. P., Akello, J. O., Álvarez‐Rodríguez, B., & Martí‐Carreras, J. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008902 · Cited by 36
Nour, N. M. (2020) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003969 · Cited by 18
Flagged first, then by citations
Research works printed but not linked: 7
- Corman VM, 2020, Eur Secur, 25, 2000045
- Wang F, 2020, Med Sci Monit, 26, e924700
- Vogel AB, 2020, bioRxiv, 12, 421008
- 10.1038/s41586-020-2639-4 · DOI · Paper page
- Sahin U, 2020, medRxiv, 12, 20245175
- 10.1056/NEJMoa2027906 · DOI · Paper page
- Skowronski DM, 2021, N Eng J Med, 384, 10
Cited by
Sorted by citations
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Jeong, M., Lee, Y., Park, J., Jung, H., & Lee, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114990 · Cited by 232
Bansal, S., Perincheri, S., Fleming, T. P., Poulson, C., Tiffany, B. R., Bremner, R. M., & Mohanakumar, T. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100637 · Cited by 150
Two centuries of vaccination: historical and conceptual approach and future perspectives
Montero, D. A., Vidal, R. M., Velasco, J., Carreño, L. J., Torres, J. P., O., M. A. B., Tovar-Rosero, Y.-Y., Oñate, A. A., & O’Ryan, M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1326154 · Cited by 171
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 111
Metadata
- Authors
- Teo, S. P.
- Affiliations
- Raja Isteri Pengiran Anak Saleha Hospital (BN)
- Corresponding author
- Teo, Shyh Poh
- ORCID
- Teo, Shyh Poh
- Venue
- Journal of Pharmacy Practice
- Publisher
- SAGE Publications
- Published
- 2021-04-12
- Volume
- 35
- Issue
- 6
- Pages
- 947-951
- ISSN
- 0897-1900 (ISSN-L)
- 1531-1937
- OpenAlex
- W3154719862
- Cited by
- 191
- References
- 26
- Citations by year
- 2026: 24 · 2025: 42 · 2024: 35 · 2023: 39 · 2022: 37 · 2021: 14
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Pharmacy Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 mRNA vaccine, BNT162b2, mRNA-1273, SARS-CoV-2, vaccine development, vaccine efficacy, immunogenicity, vaccine safety, emergency use authorization, vaccine thermostability, underrepresented groups
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Humans, RNA, Viral, United States, Viral Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
